These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15378186)

  • 1. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
    Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
    Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
    Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
    Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
    Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
    Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study.
    Sanguineti G; Franzone P; Marcenaro M; Foppiano F; Vitale V
    Strahlenther Onkol; 2003 Jul; 179(7):464-70. PubMed ID: 12835883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
    Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
    Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients.
    Goldner G; Tomicek B; Becker G; Geinitz H; Wachter S; Zimmermann F; Wachter-Gerstner N; Reibenwein J; Glocker S; Bamberg M; Feldmann H; Pötzi R; Molls M; Pötter R
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):78-83. PubMed ID: 17189064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
    Singh AK; Ménard C; Guion P; Simone NL; Smith S; Crouse NS; Godette DJ; Cooley-Zgela T; Sciuto LC; Coleman J; Pinto P; Albert PS; Camphausen K; Coleman CN
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1008-13. PubMed ID: 16730138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
    Ben-Josef E; Han S; Tobi M; Shaw LM; Bonner HS; Vargas BJ; Prokop S; Stamos B; Kelly L; Biggar S; Kaplan I
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1160-4. PubMed ID: 12128116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
    Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.